The BULLSEYE trial and PSMA radioligands

Dr. Barbara Melão (Brazil) and Dr. Danny Mena (Mexico) open Season 2 with GU oncology and the latest advances in prostate cancer care.
Key insights
- The rationale behind the BULLSEYE trial
- Key differences between lutetium and terbium
- Understanding affinity versus toxicity
- Follow-up strategies for patients with PSMA PET








